Arcellx (ACLX) Preferred Stock Liabilities (2021)
Arcellx's quarterly Preferred Stock Liabilities came in at $28.9 million in Q4 2021, down 66.15% quarter-over-quarter from $85.4 million in Q3 2021.
Arcellx has reported Preferred Stock Liabilities for 1 years, with the latest figure at $28.9 million in Q4 2021.
- For the quarter ending Q4 2021, Preferred Stock Liabilities changed N/A year-over-year to $28.9 million; the trailing twelve-month figure through Dec 2021 stood at $28.9 million (changed N/A YoY), and the FY2021 full-year result was $28.9 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q4 2021 stood at $28.9 million, down from $85.4 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $91.2 million in Q1 2021, with the low at $28.9 million in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 28.89 Mn |
| Sep 30, 2021 | 85.37 Mn |
| Jun 30, 2021 | 85.37 Mn |
| Mar 31, 2021 | 91.19 Mn |